Comparative in vivo mutagenicity testing by SCE and micronucleus induction in mouse bone marrow.
The treatment of mice with repeated injections of BUdR and FUdR allows for the demonstration  of differentially stained metaphases from bone marrow after FPG (fluorescence plus Giemsa; Perry and Wolff, 1974) treatment. Thus, it is possible to determine the number of SCE's under in vivo conditions, which appears as a very promising system for mutagenicity testing. We studied the response of this system in comparison to the micronucleus test using six mutagenic agents: triaziquone, cyclophosphamide (CP),  dimethylphenyltriazene  (PDMT), methylnitronitrosoguandine (MNNG), dimethylnitrosamine (DMNA), and diethylnitrosamine (DENA). With the exception of MNNG and DENA, all these agents induce both, SCE and micronuclei, MNNG and and DENA being ineffective in both systems. The most potent SCE-inducing agent was triaziquone, followed by PDMT, CP, and DMNA. The quantitative comparison indicates that SCE are induced at  1/10-1/100 of the concentrations which are required for the detection of micronuclei.
D000818:Animals; D001973:Bromodeoxyuridine / Q000494:pharmacology; D002842:Chromatids / Q000187:drug effects*; D002869:Chromosome Aberrations; D003434:Crossing Over, Genetic / Q000187:drug effects*; D003520:Cyclophosphamide / Q000494:pharmacology; D004052:Diethylnitrosamine / Q000494:pharmacology; D004128:Dimethylnitrosamine / Q000494:pharmacology; D004353:Drug Evaluation, Preclinical / Q000379:methods; D005467:Floxuridine / Q000494:pharmacology; D008769:Methylnitronitrosoguanidine / Q000494:pharmacology; D051379:Mice; D009153:Mutagens; D014226:Triazenes / Q000494:pharmacology; D014228:Triaziquone / Q000494:pharmacology
D009153:Mutagens; D014226:Triazenes; D005467:Floxuridine; D008769:Methylnitronitrosoguanidine; D004052:Diethylnitrosamine; D003520:Cyclophosphamide; D014228:Triaziquone; D001973:Bromodeoxyuridine; D004128:Dimethylnitrosamine